REPLIGEN CORP (RGEN)
US7599161095 - Common Stock
RGEN gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 59 industry peers in the Life Sciences Tools & Services industry. RGEN has an average financial health and profitability rating. RGEN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year RGEN was profitable.
RGEN had a positive operating cash flow in the past year.
RGEN had positive earnings in each of the past 5 years.
Each year in the past 5 years RGEN had a positive operating cash flow.
1.2 Ratios
The Return On Assets of RGEN (1.47%) is better than 69.49% of its industry peers.
RGEN's Return On Equity of 2.11% is fine compared to the rest of the industry. RGEN outperforms 72.88% of its industry peers.
Looking at the Return On Invested Capital, with a value of 0.88%, RGEN is in the better half of the industry, outperforming 64.41% of the companies in the same industry.
RGEN had an Average Return On Invested Capital over the past 3 years of 5.35%. This is below the industry average of 9.75%.
The last Return On Invested Capital (0.88%) for RGEN is well below the 3 year average (5.35%), which needs to be investigated, but indicates that RGEN had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.47% | ||
| ROE | 2.11% | ||
| ROIC | 0.88% |
ROA(3y)4.76%
ROA(5y)3.79%
ROE(3y)6.39%
ROE(5y)5.02%
ROIC(3y)5.35%
ROIC(5y)4.31%
1.3 Margins
With a decent Profit Margin value of 6.51%, RGEN is doing good in the industry, outperforming 74.58% of the companies in the same industry.
In the last couple of years the Profit Margin of RGEN has declined.
RGEN has a better Operating Margin (4.93%) than 67.80% of its industry peers.
In the last couple of years the Operating Margin of RGEN has declined.
RGEN has a Gross Margin of 45.80%. This is comparable to the rest of the industry: RGEN outperforms 49.15% of its industry peers.
In the last couple of years the Gross Margin of RGEN has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 4.93% | ||
| PM (TTM) | 6.51% | ||
| GM | 45.8% |
OM growth 3Y-12.31%
OM growth 5Y-1.83%
PM growth 3Y-26.44%
PM growth 5Y-5.32%
GM growth 3Y-4.81%
GM growth 5Y-2.29%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), RGEN is destroying value.
The number of shares outstanding for RGEN has been increased compared to 1 year ago.
Compared to 5 years ago, RGEN has more shares outstanding
Compared to 1 year ago, RGEN has a worse debt to assets ratio.
2.2 Solvency
RGEN has an Altman-Z score of 7.48. This indicates that RGEN is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 7.48, RGEN belongs to the best of the industry, outperforming 89.83% of the companies in the same industry.
The Debt to FCF ratio of RGEN is 7.74, which is on the high side as it means it would take RGEN, 7.74 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 7.74, RGEN is in the better half of the industry, outperforming 62.71% of the companies in the same industry.
RGEN has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of RGEN (0.26) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 7.74 | ||
| Altman-Z | 7.48 |
ROIC/WACC0.07
WACC11.89%
2.3 Liquidity
RGEN has a Current Ratio of 7.02. This indicates that RGEN is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of RGEN (7.02) is better than 84.75% of its industry peers.
RGEN has a Quick Ratio of 5.75. This indicates that RGEN is financially healthy and has no problem in meeting its short term obligations.
RGEN has a Quick ratio of 5.75. This is amongst the best in the industry. RGEN outperforms 83.05% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.02 | ||
| Quick Ratio | 5.75 |
3. Growth
3.1 Past
The earnings per share for RGEN have decreased strongly by -47.26% in the last year.
RGEN shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 18.51% yearly.
RGEN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -20.29%.
RGEN shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 26.91% yearly.
EPS 1Y (TTM)-47.26%
EPS 3Y1.39%
EPS 5Y18.51%
EPS growth Q2Q-51.47%
Revenue 1Y (TTM)-20.29%
Revenue growth 3Y20.37%
Revenue growth 5Y26.91%
Revenue growth Q2Q-16.63%
3.2 Future
Based on estimates for the next years, RGEN will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.72% on average per year.
RGEN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.54% yearly.
EPS Next Y-14.2%
EPS Next 2Y10.65%
EPS Next 3Y16.72%
EPS Next 5YN/A
Revenue Next Year-0.31%
Revenue Next 2Y7.7%
Revenue Next 3Y10.54%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 95.76, RGEN can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Earnings ratio of RGEN indicates a somewhat cheap valuation: RGEN is cheaper than 66.10% of the companies listed in the same industry.
RGEN's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 25.20.
RGEN is valuated quite expensively with a Price/Forward Earnings ratio of 111.60.
Compared to the rest of the industry, the Price/Forward Earnings ratio of RGEN indicates a somewhat cheap valuation: RGEN is cheaper than 61.02% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 21.63. RGEN is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 95.76 | ||
| Fwd PE | 111.6 |
4.2 Price Multiples
RGEN's Enterprise Value to EBITDA ratio is in line with the industry average.
The rest of the industry has a similar Price/Free Cash Flow ratio as RGEN.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 123.45 | ||
| EV/EBITDA | 92.4 |
4.3 Compensation for Growth
RGEN has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as RGEN's earnings are expected to grow with 16.72% in the coming years.
PEG (NY)N/A
PEG (5Y)5.17
EPS Next 2Y10.65%
EPS Next 3Y16.72%
5. Dividend
5.1 Amount
No dividends for RGEN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
REPLIGEN CORP
NASDAQ:RGEN (4/25/2024, 7:14:30 PM)
After market: 165.66 0 (0%)165.66
-2.2 (-1.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap9.25B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 95.76 | ||
| Fwd PE | 111.6 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)5.17
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.47% | ||
| ROE | 2.11% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 4.93% | ||
| PM (TTM) | 6.51% | ||
| GM | 45.8% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 7.02 | ||
| Quick Ratio | 5.75 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-47.26%
EPS 3Y1.39%
EPS 5Y
EPS growth Q2Q
EPS Next Y-14.2%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-20.29%
Revenue growth 3Y20.37%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y